Benitec Reports Positive Phase 1b/2a Results For BB-301 In Oculopharyngeal Muscular Dystrophy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 13 2024
0mins
Source: Business Insider
Clinical Trial Results: Benitec Biopharma Inc. reported positive outcomes in a Phase 1b/2a study of BB-301 for Oculopharyngeal Muscular Dystrophy, with two subjects showing significant improvements in swallowing after receiving the low-dose gene therapy.
Safety and Efficacy: The treatment was well-tolerated with no significant adverse events, and both subjects demonstrated clinically meaningful enhancements in their swallowing abilities over time, as measured by various scoring systems.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
